Journal article icon

Journal article

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.

Abstract:

BACKGROUND: The amyloid-beta peptide Abeta(42) has been implicated in the pathogenesis of Alzheimer's disease (AD). We aimed to test the effects of tarenflurbil, a selective Abeta(42)-lowering agent (SALA), on cognition and function in patients with mild to moderate AD. METHODS: 210 patients living in the community who had a mini-mental state examination (MMSE) score of 15-26 were randomly assigned to receive tarenflurbil twice per day (400 mg [n=69] or 800 mg [n=70]) or placebo (n=71) for 12...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Neuroscience
Role:
Author
Expand authors...
Journal:
The Lancet. Neurology
Volume:
7
Issue:
6
Pages:
483-493
Publication date:
2008-06-05
DOI:
EISSN:
1474-4465
ISSN:
1474-4422
URN:
uuid:15459697-72fb-458c-beb5-285dc7e5717b
Source identifiers:
34222
Local pid:
pubs:34222

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP